Guanosine

Guanosine

SCHEMBL1030863

Nc1nc2c(ncn2[C@@H]2O[C@@H]3C(O)C3(O)C2O)c(=O)[nH]1.Nc1nc2c(ncn2[C@@H]2O[C@H](CO)C(O)C2O)c(=O)[nH]1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.63
▸ HINT1 P49773 4/20 0.58
▸ NT5E P21589 2/20 0.58
▸ GSK3A P49840 2/20 0.55
▸ RPS6KA3 P51812 2/20 0.55
▸ MAPK14 Q16539 2/20 0.55
▸ PNP P00491 2/20 0.55
▸ PAX8 Q06710 1/20 0.55
▸ TGM2 P21980 1/20 0.54
▸ LMNA P02545 1/20 0.52
▸ HIF1A Q16665 1/20 0.52
▸ ADORA2A P29274 2/20 0.52
▸ ADORA3 P0DMS8 1/20 0.52
▸ ADORA2B P29275 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guanosine SCHEMBL12959061 0.90 HPGD (0.76) HPGDHINT1NT5EGSK3ARPS6KA3
Guanosine SCHEMBL5550180 0.90 HPGD (0.76) HPGDHINT1NT5EGSK3ARPS6KA3
Guanosine SCHEMBL10811044 0.90 HPGD (0.76) HPGDHINT1NT5EGSK3ARPS6KA3
Guanosine SCHEMBL24049417 0.90 HPGD (0.76) HPGDHINT1NT5EGSK3ARPS6KA3
Guanosine SCHEMBL278157 0.90 HPGD (0.76) HPGDHINT1NT5EGSK3ARPS6KA3
Guanosine SCHEMBL24049608 0.90 HPGD (0.76) HPGDHINT1NT5EGSK3ARPS6KA3
Guanosine SCHEMBL24049416 0.90 HPGD (0.76) HPGDHINT1NT5EGSK3ARPS6KA3
Guanosine SCHEMBL24049467 0.90 HPGD (0.76) HPGDHINT1NT5EGSK3ARPS6KA3
Guanosine SCHEMBL20750695 0.90 HPGD (0.76) HPGDHINT1NT5EGSK3ARPS6KA3
Guanosine SCHEMBL7062800 0.90 HPGD (0.76) HPGDHINT1NT5EGSK3ARPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178710-A1 SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2012-07-12 — — US disclosed
EP-2448954-A1 SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF Rutgers, The State University of New Jersey (US) 2012-05-09 — — EP disclosed
WO-2011003025-A1 SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2011-01-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178710-A1 SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF TYMP, DTYMK, MTAP HPGD 1251/4885HINT1 161/4885NT5E 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback